by The global small molecule innovator CDMO market size was valued at USD 41.1 billion in 2020, and is predicted to be worth around USD 73.9 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39117
Table of Contents
Small Molecule innovator CDMO Market Growth Factors
The COVID-19 pandemic has significantly impacted market growth. During this crisis, CDMOs are playing an important role in meeting the needs of pharmaceutical companies, biotech companies, and other end users. These have been working diligently towards the development of small-molecule drugs against SARS-CoV-2 since the end of 2019.
COVID-19 has caused a significant impact on the API CDMO market where China was a key performing country in contract manufacturing of APIs. In China, due to a strict government-imposed lockdown, 44 firms became non-operational and several governments chose to boycott APIs manufactured in China. To combat this shortage, several countries have started manufacturing their own APIs. COVID-19 has changed supply chains but has also boosted the API CDMO market. With the growing demand for outsourcing by pharma companies, CDMOs are now focusing more on continuous bioprocessing and process intensification.
There was unprecedented growth in 2020 due to the COVID-19 pandemic. The EFCG reported that around 80% of chemicals used to make drugs sold in Europe are supplied from India and China. The major factors fueling the growth of this market include increasing pharmaceutical R&D investment and the rising incidence of cancer and age-related disorders across the globe. Another factor fueling market growth is the growing demand for small molecule drugs. In 2020, small molecule drugs dominated new molecular entities (NMEs) approvals.
Small Molecule innovator CDMO Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 73.9 billion by 2030 |
| Growth Rate | CAGR of 6.4% From 2022 to 2030 |
| Largest Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, Stage type, Customer type, Therapeutic area |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Lonza Group Ltd.; Patheon; Cambrex Corporation; Catalent Inc.; Siegfried holdings AG; Recipharm AB; Corden Pharma International; Boehringer Ingelheim; Piramal Pharma Solutions; Covance Inc.; Wuxi AppTec ; Thermo Fisher Pantheon |
By Product Analysis
The small molecule API segment dominated the market and accounted for a revenue share of over 60.0% in 2021. This growth can primarily be attributed to the rising demand for small molecule innovators.
The small molecule drug product segment is expected to expand at a CAGR of 6.0% over the forecast period. The small molecule drug substances have become more complex, with manufacturing methods becoming more specialized.
By Stage Type Analysis
The clinical segment dominated the market in 2021 and held a revenue share of over 50.0%. The clinical phase represents the organization’s future, where mistakes can result in products not making it through the clinic or clinical programs being delayed, not to mention the impact on patients.
The commercial segment is projected to register the fastest growth rate of 7.2% over the forecast period. Rising demand for outsourcing by small- and medium-sized pharmaceutical companies is one of the factors driving the segment.
The labor paradigm that had previously serviced R&D activities will not work in the commercial space. This is where the role of CDMOs comes into play. CDMOs offer specialized expertise, time-saving, and cost-efficiency, which is likely to propel the segment growth during the forecast period.
By Customer Type Analysis
The pharmaceutical segment accounted for over 90.0% share of the global revenue in 2021. The biotechnology segment includes biotechnology firms. In these firms, the production of small molecules is also done.
The segment’s expansion is being fueled by factors such as rising biopharmaceutical demand and enhanced molecular efficiency. Furthermore, this growth can be attributed to large investments in the biotechnology and biopharmaceutical industries.
By Therapeutic Area Analysis
The oncology segment held the largest revenue share of over 40.0% in 2021 and is anticipated to register the fastest growth rate over the forecast period owing to the increasing number of cancer cases globally.
Increased government reimbursement policies and a rise in financing for the development of small molecule oncology therapies are other factors boosting the segment growth. In 2018, 42 NCEs were approved, and 38 in 2019 – a significant rise over the recent average of 25-35 NCE approvals per year.
The industry is also being driven by supportive government reimbursement policies and financing towards the development of small molecule oncology therapies. In addition, CDMOs are increasing their investments in facilities for the production of highly powerful APIs (HPAPIs).
By Regional Analysis
Asia Pacific accounted for the largest revenue share of over 40.0% in 2021. A key factor fueling the regional market growth is the significantly cheaper manufacturing costs than North America and Europe and favorable laws.
North America held the second-largest revenue share in 2021. It is one of the major contributors to the growth of the global market. It is characterized by the presence of several established pharmaceutical, biotechnology, and medical device companies.
Read also @ Home Infusion Therapy Market Opportunities & Forecast 2021-2030
Major Key Players Covered in The Small Molecule innovator CDMO Market Report include
- Piramal Pharma Solutions
- Corden Pharma
- Wuxi AppTec
- Cambrex Corporation
- Recipharm AB
- Thermo Fisher Pantheon
- Lonza Group Ltd.
- Catalent Inc.
- Siegfried Holding AG
- Boehringer Ingelheim
- Covance Inc.
Small Molecule innovator CDMO Market Segmentation
- By Product
- Small Molecule API
- Small Molecule Drug Product
- Oral Solid Dose
- Semi-Solid Dose
- Liquid Dose
- Others
- By Stage Type
- Preclinical
- Clinical
- Phase I
- Small
- Medium
- Large
- Phase II
- Small
- Medium
- Large
- Phase III
- Small
- Medium
- Large
- Phase I
- Commercial
- By Customer Type
- Pharmaceutical
- Small
- Medium
- Large
- Biotechnology
- Pharmaceutical
- By Therapeutic Area
- Cardiovascular Diseases
- Oncology
- Respiratory Disorders
- Neurology
- Metabolic Disorders
- Infectious Diseases
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- India
- Japan
- China
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Customer Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Small Molecule Innovator CDMO Market, By Product
7.1. Small Molecule Innovator CDMO Market, by Product, 2021-2030
7.1.1. Small Molecule API
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Small Molecule Drug Product
7.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Small Molecule Innovator CDMO Market, By Stage Type
8.1. Small Molecule Innovator CDMO Market, by Stage Type, 2021-2030
8.1.1. Preclinical
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Clinical
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Commercial
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Small Molecule Innovator CDMO Market, By Customer Type
9.1. Small Molecule Innovator CDMO Market, by Customer Type, 2021-2030
9.1.1. Pharmaceutical
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Biotechnology
9.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Small Molecule Innovator CDMO Market, By Therapeutic Area
10.1. Small Molecule Innovator CDMO Market, by Therapeutic Area, 2021-2030
10.1.1. Cardiovascular Diseases
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Oncology
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Respiratory Disorders
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Neurology
10.1.4.1. Market Revenue and Forecast (2019-2030)
10.1.5. Metabolic Disorders
10.1.5.1. Market Revenue and Forecast (2019-2030)
10.1.6. Infectious Diseases
10.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Small Molecule Innovator CDMO Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.1.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.1.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.6.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.1.6.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.2.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.2.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.8.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.2.8.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.3.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.3.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.8.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.3.8.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.4.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.4.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.8.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.4.8.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.5.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.5.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.6.2. Market Revenue and Forecast, by Stage Type (2019-2030)
11.5.6.3. Market Revenue and Forecast, by Customer Type (2019-2030)
11.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
Chapter 12. Company Profiles
12.1. Piramal Pharma Solutions
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Corden Pharma
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Wuxi AppTec
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Cambrex Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Recipharm AB
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Thermo Fisher Pantheon
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Lonza Group Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Catalent Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Siegfried Holding AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Boehringer Ingelheim
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39117
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
